You are here

Home » Content

HEMODİYALİZ HASTALARİNDA PLAZMA SERBEST KARNITIN DÜZEYLERİ VE KARNITIN TEDAVİSİNİN LIPID PROFİLİNE ETKİSİ

PLASMA CARNITINE LEVELS AND THE EFFECT OF CARNITINE TREATMENT ON LIPID PROFILE IN HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1995

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
L-Carnitine is an amino acid derivative which ta¬kes part in the transfer of long-chain fatty acids from cytosol to mitochondrial matrix through the inner mi-tochondrial membrane. Plasma and tissue carnitine levels of patients hemodialysed for end-stage renal fa¬ilure are lower than those of healthy subjects. It is proposed that carnitine supplementation may improve dyslipidemias frequently seen in this patient group. In this trial the effect of L-Carnitine supplementati¬on 1 gram/day orally for 16 weeks on plasma free carnitine, total cholesterol, triglyceride, HDL-choles-terol, LDL-cholesterol, apolipoprotein A-l and apoli-poprotein B-100 levels of 17 chronic hemodialysis pa¬tients (10 female, 7male) was studied. A significant rise in plasma free carnitine and significant fall in total cholesterol, LDL-cholesterol and apolipoprotein B-100 levels were observed. Triglyce-ride, HDL-cholesterol and apolipoprotein A-l 00 le¬vels did not change significantly. These results indicate that L-Carnitine supplemen¬tation may have a part, along with other treatment modalities, in the therapy of dyslipidemia, a major in¬dependent risk factor for coronary artery disease, in hemodialysis patients for whom coronary heart disea¬se is an important cause of morbidity and mortality.
Bookmark/Search this post with
Abstract (Original Language): 
Kamilin uzun zincirli yağ asitlerinin mitokondri iç zarından geçişinde görev alan bir amino asit türevi¬dir. Son dönem böbrek yetmezliği nedeni ile hemodi¬yalize giren hastalarda plazma ve doku karnitin dü¬zeylerinin sağlıklı bireylere göre düşük olduğu bilinmektedir. Karnitin tedavisi ile bu hasta populasyonunda sık görülen dislipidemilerde düzelme sağlanabileceği ile¬ri sürülmektedir. Bu çalışmada en az 1 yıldır hemodiyalize girmekte olan 17hastada (10 kadın, 7erkek) 16 hafta süre ile 1 gram/gün Karnitin uygulanmasının plazma serbest karnitin, Total kolesterol, trigliserid, HDL-kolesterol, LDL-kolesterol, apolipoprotein A-l ve apolipoprotein B-100 düzeylerine etkisi incelendi. Serbest karnitin düzeylerinde önemli yükselme, total kolesterol, LDL-kolesterol ve apolipoprotein B-100 düzeylerinde önemli düşme gözlenirken trigliserid, HDL-kolesterol ve apolipoprotein A-l düzeylerinde önemli değişiklik olmadı. Bu sonuçlar hemodiyaliz hastalarının morbidite ve mortalitesinde önemli bir yer tutan koroner arter hastalığının major bağımsız risk faktörlerinden biri olan dislipideminin tedavisinde diğer tedavi modalite-leri ile birlikte kamilinin de yeri olabileceğini göster¬mektedir.
FULL TEXT (PDF): 
PDF icon pdf_tndt_75.pdf
  • 1
33-36
  • Turkish

REFERENCES

References: 

1. Siliprandi N. Carnitine as a drug affecting lipid metabolism: General consideration. In: Paoletti R (ed), Hypoli-pidemic drugs; Therapeutic selectivity and risk/benefit assessment. Raven Press, New York 1982, pp 265-268.
2. Williams ES, Luft FC. The effects of chronic uremia on fatty acid metabolism in the heart. Kidney Int 1976; 10:
568.
3. Böhmer T, Ryding A, Solberg HE. Carnitine levels in human serum in health and disease. Clin Chim Acta 1974 ; 57: 55.
4. Böhmer T, Bergremn H, Eiklid K. Carnitine deficiency induced during intermittent hemodialysis for renal failu¬re. Lancet 1978; 1: 126.
5. Battal LL, Hussey JL, Shrago E. Perturbation of serum carnitine levels in human adults by chronic renal disease and dialysis therapy , Am J Clin Nutr 1981; 34: 1314¬1320.
6. Daubresse JC, Lerson G, Plomteux G, Luyckx AS, Le-febvre PJ. Lipids and lipoprotein in chronic uremia. A study of the influence of hemodialysis, Eur J Clin Invest 1976; 6:159.
7. Brunzell JD, Albers JJ, Haas LB, Goldberg AP, Agadoa L, Sherrard DJ. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903.
8. Bagdade JD, Albers JJ. Plasma high-density lipoprotein concentrations in chronic hemodialysis and renal trans¬plant patients. N Eng J Med 1977; 29: 1436-1439.
9. Frank WM, Rao TKS, Manis T, Delano BG, Avram
MM, Saxena AK, Carter AC, Friedman EA. Relationship of plasma lipids to renal function and lenght of time on maintanance hemodialysis. Am J Clin Nutr 1978 ; 31: 1886-1892.
10. Gutman RA, Uy A, Shalhoub RJ, Wade AD, O' Connel JMB, Recont L. Hypertrigliceridemia in chronic non-nephrotic renal failure. Am J Clin Nutr 1973; 26: 165¬172.
35
11. Ibels LS, Simons LA, King JO, Williams PF, Neale FC, Stewart JH. Studies on the nature and causes of hyperli-pidemia in uremia, maintenance dialysis, and renal transplantation. Quart J Med 1975 ; 44: 601-614.
12. Ponticelli C, Barbi G, Cantaluppi A, Donati C, Annoni G, Brancaccio D. Lipid abnormalities in maintenanca di¬alysis patients and renal transplant recipients. Kidney Int 1978 ; 13 (Suppl 8): S72-78.
13. Gusmano R, Oleggini R, Perfumo F: Plasma carnitine concentration and dyslipidemia in children on mainte¬nance hemodialysis, J Pediatr 1981 ;99: 429-432.
14. Bertoli M, Batistella PA, Vergani L, et al. Carnitine de¬ficiency induced during hemodialysis and hyperlipide-mia: Effect of replacement therapy. Am J Clin Nutr 1981
; 34: 1496-1500.
15. Maebashi M, Imamura A, Yoshinaga K, et al. Carnitine depletion as a probable cause of hyperlipidemia in ure-mic patients on maintenance hemodialysis. Tohoku J Exp Med 1983 ; 139: 33A2.
16. Chan MK, Persaud JW, Varghese Z, Baillod RA, Moor-head JF. Response patterns to DL-Camitine in patients on maintenance hemodialysis. Nephron 1982; 30: 240¬243.
17. Guamieri GF, Ranieri F, Toigo G, et al. Lipid lowering effct of carnitine in chronically uremic patients treated with maintenance hemodialysis. J Clin Nutr 1980 ; 33: 1489-1492.
18. Bougneres PF. Lacour B, Di Giulio S, Assan R. Hypoli-pemic effect of carnitine in uremic patients. Lancet
1979; 1: 1401-1402.
19. Lacour B, Di Guilio S, Chanard J, et al. Carnitine impro¬ves lipid anomalies in hemodialysis patients. Lancet 1980; 2: 763-765.
20. Albertazzi A, Capelli P, Di Paolo B, Paola P. Tondi P, Vaccario O. Endocrine-metabolic effects of L-Carnitine in patients on regular dialysis treatment. Proc Eur Dial Transplant Assoc 1982 ;19: 302-307.
21. Vacha GM, Giorcelli G, Siliprandi N, Corsi M. Favorab¬le effects of L- Carnitine treatment on hypertrigliceride-mia in hemodialysis patients. Decisive role of low levels of high- density lipoprotein cholesterol. Am J Clin Nutr 1983; 38: 532-540.
22. Caruso U, Cravotto E, Tisone G, et al. Long term treat¬ment with L-Carnitine in uremic patients undergoing he-modialysis. Effects on lipid pattern. Curr Ther Res 1983 ;
33: 1098-1103.
23. Casciani CV, Caruso U, Cravotto E et al. L-Carnitine in hemodialysis patients. Arzneimittel-Forshung 1982 ; 32:
293-297.
24. Bellinghieri G, Savica V, Mallamace A, et al. Correlation between increased serum and tissue L-Camitine levels and improved muscle symptoms in hemodialyzed pati¬ents. Am J Clin Nutr 1983 ; 38: 523-531.
25. Yderstraede KB, Pederson FB, Dragsholt C, Trostman A, Laier E, Larsen HF. The effect of L-Carnitine on lipid metabolism in patients on chronic hemodialysis. Nephrol Dial Transplant 1987 ; 1: 238-241.
26. Nilsson-Ehle P, Cederblad G, Fagher B, Monti M,
Thysell H. Plasma proteins, liver function and glucose metabolism in hemodialysis patients. Lack of effect of L-Camitine supplementation. Scand J Clin Lab Invest
1985;45:179-184.
27. Aubia J, Masramon J, Lloveras J, Llorach M, Andolz P. Carnitine in hemodialysis patients. Lancet 1980 ; 2: 1028-1029.
28. Weschler A, Aviram M, Levin M, Better OS, Brook JG.
High dose of L-Carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on he-modialysis. Nephron 1984 ; 38: 120-124.
29. Wanner C, Forstner-Wanner S, Schaeffer G, Schollme-yer P, Hörl WH. Serum free carnitine, carnitine esters and lipids in patients on peritoneal and hemodialysis. Am
J Nephrol 1986; 16: 206-211.
30. Savice V, Bellinghieri G, Di Stefano C. Plasma and muscle carnitine levels in hemodialysis patients with morphological-ultrastructural examination of muscle samples. Nephron 1983 ; 35: 232-236.
31. Bazzi C, Di Donato S, Casiglione A, Corsi M, D' Amico G. Carnitine metabolism in short and long term mainte¬nance hemodialysis. In: Borum PR (ed), Clinical As¬pects of Human Carnitine Deficiency. Pergamon Press, New York 1986; p 245.
32. Wanner C, Försstner-Wanner S, Rössle C, Fürst P, Scho¬ol-Meyer P, Hörl WH: Carnitine metabolism in patients with chronic renal failure : Effect of L-Camitine supple¬mentation. Kidney Int 32 (suppl 22): S 132-135,1987.
33. Vacha GM, Giorcelli G, D' Iddio S, Corsi M. Effects of
long term treatment with L- Carnitine on lipid pattern of patients undergoing hemodialysis. Pro Eur Dial Transpl
Assoc 1985 ; 22: 121-126.
34. Avogaro P, Bitollo Bon. Cazzolato G, Quinci GB. Are apolipoproteins better discriminators than lipids for athe-rosklerosis ? Lancet 1979; i: 901.

Thank you for copying data from http://www.arastirmax.com